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Abstract
Transplantation of human islets is an attractive alternative to daily insulin injections for patients with type 1 diabetes.
However, the majority of islet recipients lose graft function within five years. Inflammation is a primary contributor to graft
loss, and inhibiting pro-inflammatory cytokine activity can reverse inflammation mediated dysfunction of islet grafts. As
mesenchymal stem cells (MSCs) possess numerous immunoregulatory properties, we hypothesized that MSCs could protect
human islets from pro-inflammatory cytokines. Five hundred human islets were co-cultured with 0.5 or 1.0610
6 human
MSCs derived from bone marrow or pancreas for 24 hours followed by 48 hour exposure to interferon-c, tumor necrosis
factor-a and interleukin 1b. Controls include islets cultured alone (6 cytokines) and with human dermal fibroblasts (6
cytokines). For all conditions, glucose stimulated insulin secretion (GSIS), total islet cellular insulin content, islet b cell
apoptosis, and potential cytoprotective factors secreted in the culture media were determined. Cytokine exposure
disrupted human islet GSIS based on stimulation index and percentage insulin secretion. Conversely, culture with 1.0610
6
bMSCs preserved GSIS from cytokine treated islets. Protective effects were not observed with fibroblasts, indicating that
preservation of human islet GSIS after exposure to pro-inflammatory cytokines is MSC dependent. Islet b cell apoptosis was
observed in the presence of cytokines; however, culture of bMSCs with islets prevented b cell apoptosis after cytokine
treatment. Hepatocyte growth factor (HGF) as well as matrix metalloproteinases 2 and 9 were also identified as putative
secreted cytoprotective factors; however, other secreted factors likely play a role in protection. This study, therefore,
demonstrates that MSCs may be beneficial for islet engraftment by promoting cell survival and reduced inflammation.
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Introduction
Islet transplantation is an attractive alternative treatment to
daily insulin injections for patients with type 1 diabetes [1].
Following the Edmonton Protocol, nearly 90% of islet transplant
recipients remained insulin independent at one year [2]; however,
only 10% of the recipients were insulin independent at five years’
post transplant [3]. This loss of graft function may be attributed to
various factors including toxicity of immunosuppressive drugs [3],
immune rejection [3], and inadequate supply of islet precursor
cells for b cell replacement [4]. However, immediately after
transplantation, inflammation plays a significant role in the loss of
islet function [5,6]. This inflammatory response is characterized by
elevated interferon-c (IFN- c), tumor necrosis factor-a, (TNF-a)
and interleukin 1b (IL-1b) [5,7]. Rodent and human islet cells
exposed to these pro-inflammatory cytokines lose glucose re-
sponsiveness and express increased markers of apoptosis [8,9]. In
addition to b-cell cytotoxicity, these cytokines exacerbate the
inflammatory response by recruiting and activating immune cells
such as macrophages [5,10]. Decreasing cytokine expression,
inhibiting cytokine activity or inhibiting macrophage activity
improves the function of transplanted islets [5,7,10]. Thus,
minimizing inflammation at the transplant site during engraftment
may help to prolong islet graft function and maintain long-term
insulin independence.
Control of islet graft inflammation may be achieved by co-
transplantation of islets with multipotent mesenchymal stromal
cells, also known as mesenchymal stem cells (MSCs) [11]. These
stromal cells are connective tissue derived stem cells with
immunomodulatory and regenerative properties [12,13]. They
also secrete anti-inflammatory proteins and suppress the activity of
various immune cells such as alloantigen activated T and B
lymphocytes [12,13]. Moreover, MSCs can secrete growth factors
that improve tissue survival, stimulate angiogenesis and facilitate
tissue engraftment in animal models of myocardial infarction,
diabetes and graft versus host disease [12,13].
In cell culture, the trophic effects of MSCs have also been
reported with rodent and human islets [14–18]. However, the
capacity of human MSCs to protect human islets from pro-
inflammatory cytokines has not been studied. Therefore, in this
study, we examined the cytoprotective effect of bone marrow and
pancreatic derived [19] MSCs on human islets in vitro. We co-
cultured human islets with human MSCs and measured islet cell
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cytokine cocktail. We report that MSC aggregates preserve
glucose stimulated insulin secretion (GSIS), prevent islet b cell
apoptosis, and identify possible secreted MSC factors that mediate
this protection. Thus, co-administering MSCs may be beneficial in
prolonging islet graft survival.
Materials and Methods
Ethics Statement
Human pancreases were procured from cadaveric donors after
written informed research consent was provided by donor
relatives. Written ethical approval for this research study was
provided by the University of Alberta’s Health Research Ethics
Board – Biomedical panel (study ID: Pro00001416).
Preparation of Human Islets
Human pancreases (ages ranging from 16 to 71, n=23) were
processed according to islet isolation protocols previously de-
scribed by our group [1,4]. Islet enriched fractions (10–30%
dithizone positive) were cultured in Roswell Park Memorial
Institute (RPMI) 1640 (Gibco, Carlsbad CA) medium supple-
mented with 0.5% w/v fraction V bovine serum albumin (BSA,
Sigma-Aldrich, Oakville, Canada) and 1.0% v/v insulin-trans-
ferrin-selenium (ITS, Sigma-Aldrich).
Preparation of Human Bone Marrow and Pancreatic
Derived MSCs
To prepare bone marrow derived MSCs (bMSCs), human bone
marrow was extracted from six patients aged 24, 42, 45, 46, 62,
and 69 years (Division of Orthopedic Surgery, University of
Alberta) following informed consent [20]. For expansion, cells
were plated in Modified Essential Medium alpha (MEMa, Cellgro
Manassas, VA) supplemented with 2.5 ng/mL basic fibroblast
growth factor (bFGF, Millipore, Billerica, MA), 10% fetal bovine
serum (FBS, Gibco), 1 mM sodium pyruvate (Gibco), 10 mM
HEPES (Gibco), 100 U penicillin/1000 U streptomycin (Biowhit-
taker, Walkersville, MD) at a density of 166,000 cells per cm
2.
Non-adherent cells were removed by changing the medium every
2–3 days. Once conuent, the cell monolayer was washed with
versene and was detached with 0.05% v/v trypsin-EDTA
(Invitrogen, Carlsbad CA). Cells were counted and re-seeded into
supplemented MEMa culture medium at a density of 5000–
10000 cells/cm
2.
To prepare human pancreatic derived MSCs (pMSCs), human
pancreatic tissue from islet depleted fractions were obtained from
seven donors aged 36, 44, 49, 49, 52, 57, and 64 years and were
cultured in RPMI 1640 with 0.5% w/v BSA and 1.0% v/v ITS for
24 to 48 hours [19]. In our original study [19], pMSCs expressed
surface markers characteristic of MSCs and differentiated into
osteocytes, adipocytes and chondrocytes. To expand pMSCs,
these cell preparations were cultured for 5 to 8 days in RPMI 1640
with 10% FBS, 20 ng/mL epidermal growth factor (EGF, R&D
Systems, Minneapolis, MN), 20 ng/mL bFGF, 1 mM sodium
pyruvate, 10 mM HEPES, 100 U penicillin/1000 U streptomy-
cin, and 71.5 mM b-mercaptoethanol (Sigma-Aldrich). Once 75–
90% confluent, the cell monolayer was enzymatically detached
with 0.05% v/v trypsin-EDTA. Cells were re-plated in supple-
mented RPMI media described above at a density of 2500–
5000 cells per cm
2. Both bone marrow and pancreatic derived
MSCs from passages 2–6 were utilized for this study. All cell
cultures were maintained at 37
oC with 5% CO2 in a humidified
incubator.
To confirm that both bMSCs and pMSCs express the classical
MSC surface antigens, cells from passages 2–6 were stained with
MSC markers based on the position statement from the
International Society for Cellular Therapy (ISCT) [21]. Cells
were fixed in 4% w/v paraformaldehyde for 1 hour and washed
with phosphate buffer saline (PBS) before primary antibody
staining. Cells were stained for MSC markers CD29-PECy5
(Caltag, Carlsbad CA), CD44-FITC (Chemicon, Billerica, MA),
CD73-PE, CD90-PE (BD Biosciences, Mississauga, Canada), and
CD105-PE (Biolegend, San Diego, CA) as well as hematopoietic
lineage markers CD11b-FITC (Abcam, San Francisco CA),
CD19-PE (Abcam), CD34-FITC and CD45-PE (Caltag) for 30–
60 minutes (4
oC, protected from exposure to light). MSC marker
expression was analyzed on a BD FACScalibur flow cytometer.
For isotype controls, cells were also stained for IgG1-PE
(Cedarlane, Burlington, Canada), IgG1-FITC (Cedarlane) and
IgG1-PECy5 (Caltag).
Preparation of Human Dermal Fibroblasts
Human dermal fibroblasts were prepared and expanded from
normal skin samples of donors aged 35 and 60 in order to serve as
a negative control cell population (Division of Plastic Surgery,
University of Alberta) [22]. Fibroblasts were cultured in Dulbec-
co’s Modified Eagle Medium high glucose (DMEM 25 mM
glucose, Gibco) and detached using 0.05% v/v trypsin-EDTA. For
sub-culturing, cells were split at a ratio of 1:6 and fibroblasts at
passages 3–8 were used in this study.
Exposure of Human Islet:MSC Co-cultures to Pro-
inflammatory Cytokines
Bone marrow (bMSC) and pancreatic (pMSC) derived MSCs
were enzymatically detached from culture plates, counted, and
added (0.5, or 1.0610
6 cells) to a 100 mm low adherence culture
dish (Corning) with 500 human islets in a total volume of 10 mL.
Controls included islets cultured alone (6 cytokines) and islets co-
cultured with human dermal fibroblasts (6 cytokines). The culture
medium consisted of DMEM low glucose (5.6 mM glucose, Gibco)
with 1% FBS, 20 ng/mL EGF, 20 ng/mL bFGF, 10 mM
HEPES, 100 U penicillin/1000 U streptomycin, and 71.5 mM
b-mercaptoethanol. After 24 hours, these islet:MSC co-cultures
and islet:fibroblast co-cultures were exposed to a previously
described cocktail of pro-inflammatory cytokines [23] including
1560 ng interferon-c, 250 ng tumor necrosis factor-a, and
0.4625 ng interleukin 1b (specific activities 2.4610
6 U/mg, 5–
2610
7 U/mg, 1.16–0.54610
9 U/mg respectively; Biolegend) in
10 mL volume for 48 hours.
Characterization of Islet:MSC Co-cultures
A static incubation assay [24] was used to determine glucose
responsiveness in islet controls and in co-cultures following the 48
hour cytokine exposure. Islets, islet:MSC co-cultures and islet:fi-
broblast co-cultures were collected and washed twice by gravity
sedimentation over 30 minutes. Preparations were then divided
into representative aliquots and incubated at 37
oC for 2 hours in
1.5 mL RPMI supplemented with 2.0 mM L-glutamine, 0.5% w/
v BSA and either 2.8 mM (low) or 20.0 mM (high) glucose. Tissue
and medium were then separated by centrifugation and assayed
for their respective insulin contents by a human insulin immuno-
assay (Meso Scale Discovery, Gaithersburg, MD). The insulin
content of that secreted in the medium was normalized to that of
the total cellular insulin content [24]. To assess total cellular
insulin content, intact islets from representative aliquots were lysed
then centrifuged to remove cellular debris. Cellular insulin content
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indices were calculated by dividing the amount of insulin released
at 20.0 mM glucose by that released at 2.8 mM glucose and
insulin release (% insulin content) is reported as insulin secreted at
2.8 mM or 20.0 mM glucose divided by total cellular insulin
content.
Analysis of Islet b-cell Apoptosis by
Immunohistochemistry
Cytokine induced b cell damage was assessed by the co-
expression of insulin and TUNEL, a marker for cell apoptosis,
from human islets. After culture, paraffin sections of islets were
prepared for double immunofluorescence (IF) analysis by fixation
with 4% w/v paraformaldehyde (BDH Laboratory Supplies,
Poole, England) and embedding in 2% w/v low melting point
agarose (Sigma-Aldrich). Paraffin sections were processed and
immunostained. After rehydration, antigen retrieval for tissue
samples was performed in sodium citrate buffer (pH 6.0). The
samples were then blocked with 20% normal goat serum (NGS,
Jackson ImmunoResearch Laboratories Inc., West Grove, PA,
USA) for 1 hour in the dark. For apoptosis, an APO-BrdU
TUNEL Assay Kit (Invitrogen) was utilized, in which an
AlexaFluor 488 labeled anti-BrdU antibody was used for de-
tection. The same tissues were then stained with a guinea pig anti-
insulin antibody (Dako, Mississauga, ON, Canada) diluted at 1/
1000 in 5% NGS followed by a secondary AlexaFluor 594 mouse
anti-guinea pig antibody (Molecular Probes, Eugene, OR, USA).
Slides were coverslipped with Prolong Gold Anti-fade (Invitrogen)
to preserve fluorescence. Negative controls included sections of the
same tissues incubated without insulin primary antibodies. For the
TUNEL assay, TUNEL positive and TUNEL negative control
cells were stained to confirm TUNEL positivity. Slides were
visualized with an Axioscope II microscope equipped with an
AxioCam MRC and analyzed with Axiovision 4.6 software (Carl
Zeiss, Gottingen, Germany).
Analysis of Culture Supernatant for Cytoprotective
Factors
To assess cytoprotective factors secreted by MSCs in islet:MSC
co-cultures exposed to cytokines, factors were measured in the cell
culture supernatant and analyzed by custom immunoassay kits
(interleukin 6 (IL-6)/interleukin 10 (IL-10), hepatocyte growth
factor (HGF)/vascular endothelial growth factor (VEGF), matrix
metalloproteinase 2 (MMP2)/matrix metalloproteinases 9
(MMP9), Meso Scale Discovery). To determine base line levels,
MSCs were cultured alone as either a cell monolayer or as cell
aggregates in 6 well plates at a density of 0.2610
6 cells/2.0 mL.
Supernatant was collected from 1 and 3 day MSC cultures, and
cell debris was removed from the supernatant and collected by
centrifugation (10, 0006g, 10 minutes, 4uC). Supernatant from
islet:MSC co-cultures (the same used to measure insulin secreted
content) was collected following exposure to cytokines and also
centrifuged to remove and collect cell debris. To normalize protein
content secreted into the medium to cellular DNA, cells collected
from corresponding supernatant samples were assessed for DNA
content. To measure DNA content, cell pellets were washed twice
with citrate buffer (150 mM NaCl, 15 mM citrate, 3 mM EDTA,
pH 7.4), sonicated in DNA lysis buffer (0.5% v/v Triton x-100 in
pH 7.5 Tris HCl-EDTA) and aliquots of 25 mL and 50 mL were
assayed in duplicate with Pico Green reagent (Molecular Probes,
Carlsbad, CA) and fluorescence was detected at 485 ex./527 em.
nm. [24].
Effect of Hepatocyte Growth Factor on Human Islets
Exposed to Pro-inflammatory Cytokines
Islet cultures (500 islets in 10 mL of culture medium used for
islet:MSC co-cultures) were prepared as described above with
recombinant human hepatocyte growth factor (10 ng/mL rhHGF,
R&D Systems, Minneapolis, MN). After 24 hours, the culture
media of the islet cultures was changed. The cultures were then
treated with a second dose of rhHGF and exposed to pro-
inflammatory cytokines [23], including 1560 ng interferon-c,
250 ng tumor necrosis factor-a, and 0.4625 ng interleukin 1b
(specific activities 2.4610
6 U/mg, 5–2610
7 U/mg, 1.16–
0.54610
9 U/mg respectively; Biolegend) for 48 hours. Controls
included islets cultured alone and islets exposed to cytokines
without HGF.
Statistical Analysis
Data are presented as mean 6 SEM. Comparisons of mean
values were performed with one-way ANOVA and/or Kruskal
Wallis multiple comparisons tests with the level of significance set
at a=0.05. A Bonferroni or corrected Bonferroni analysis was
conducted for data considered significantly different between
treatment groups. All statistical analyses were performed with
STATA 11 (StataCorp LP, College Station, TX).
Results
Characterization of Bone Marrow and Pancreatic Derived
MSCs
MSC surface antigen expression [19] was analyzed by flow
cytometry for passages 2–6. Both bone marrow (n=3) and
pancreatic (n=5) derived MSCs expressed high levels of CD29,
CD73, CD90 and CD105 (.90%). However, these cells did not
express hematopoietic markers CD11b, CD19, CD34 and CD45
(,5%, Table 1).
Table 1. Characterization of cell surface antigens on human
bone marrow and pancreatic derived mesenchymal stem
cells.
Epitopes bMSC (n=3) pMSC (n=5)
MSC Markers
CD29 99.560.2 99.660.2
CD44 77.464.9 76.7612.5
CD73 99.860.0 99.960.1
CD90 96.460.6 97.463.0
CD105 98.460.5 99.560.3
Non MSC Markers
CD11b 0.960.1 0.760.2
CD19 0.960.1 0.860.2
CD34 1.260.1 1.260.1
CD45 1.560.2 4.363.8
Values are expressed as mean 6 SEM from MSCs between passages 2 and 6.
bMSCs, bone marrow mesenchymal stem cells; pMSCs, pancreatic
mesenchymal stem cells.
doi:10.1371/journal.pone.0038189.t001
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Exposed to Pro-inflammatory Cytokines
Glucose stimulated insulin secretion (GSIS) was used to assess
human islet function in a two hour static incubation assay at
2.8 mM and 20.0 mM glucose. Islets without cytokine exposure
exhibited a glucose induced stimulation index (SI) of 2.160.2
(n=7) with corresponding insulin release at 2.8 mM and 20.0 mM
glucose of 2.360.3% and 4.660.4% (n=7). Cytokine exposure
significantly altered GSIS. Exposure to cytokines significantly
increased insulin release at 2.8 mM and 20.0 mM glucose,
respectively (11.661.9% and 14.363.1%, p,0.05), resulting in
a reduced SI of 1.260.1 (p,0.05 vs. no cytokine). In contrast,
islets co-cultured with MSCs maintained GSIS, and this protective
effect was also dependent on MSC dose. In particular, islets co-
cultured with 1.0610
6 bMSCs had significantly improved GSIS
compared to cytokine treated islets (SI=2.060.2 and percentage
insulin release at 2.8 mM and 20.0 mM glucose of 3.661.6% and
6.860.9%, n=6, p,0.05). Similar effects were also observed with
pMSCs but the effect was more robust with all doses of bMSC
aggregates (Table 2). On the other hand, this protective effect was
not observed when islets were co-cultured with dermal fibroblasts.
Insulin release was elevated at both 2.8 mM and 20.0 mM
glucose, and the stimulation index was comparable to cytokine
exposed islets (Table 2). While increasing fibroblast numbers
marginally decreased percentage insulin release, the values were
not significantly different from cytokine treated islets. Recovery of
total cellular insulin content was significantly reduced after
cytokine exposure. However, recovery of insulin content from
islets co-cultured with 1.0610
6 bMSCs was not significantly
reduced compared to untreated controls (Table 2). For each co-
culture experiment, independent islet samples were assessed. In
addition, to determine the effect of MSCs on islets without
cytokines, islets were co-cultured with 1.0610
6 bMSCs or 1.0610
6
pMSCs as independent conditions. In the absence of cytokines,
GSIS from islet:MSC co-culture was not different from islet
controls. In summary, the SI for islets co-cultured with bMSCs was
2.660.4 compared to islets alone, 2.160.2; and the SI for islets co-
cultured with pMSCs was 2.460.2 compared to islets alone,
2.260.4.
Bone Marrow Derived MSCs Prevent Cytokine Induced
Islet b-cell Apoptosis
TUNEL identifies DNA fragmentation within a cell and is an
indicator of a cell undergoing apoptosis. To determine islet b cell
apoptosis, tissues were co-stained for insulin and TUNEL. Islets,
islets + cytokines, islets + bMSCs, and islets + bMSCs + cytokines
were compared. Islets cultured without cytokines exhibited few
TUNEL positive cells (Figure 1B). After pro-inflammatory
cytokine exposure, insulin and TUNEL co-expression was
observed in islets cultured alone (Figure 1F). The number of
insulin positive cells from cytokine treated islets was also decreased
compared to untreated islet controls (Figure 1D). Interestingly,
other cells within the islet that did not stain for insulin were
TUNEL positive. Changes to islet morphology were observed, as
insulin positive cells appear less organized than untreated controls
(Figure 1D, 1F). In the islets + bMSCs control, no TUNEL
staining was observed (data not shown). Insulin staining and the
islet morphology were similar to untreated islet controls. Cytokine
exposure, however, did not induce TUNEL expression from islets
co-cultured with 1.0610
6 bMSCs (Figure 1H, 1I). The number of
insulin positive cells was comparable to control tissues, and the
organization of insulin positive cells in the islet did not appear to
be affected.
Bone Marrow and Pancreatic Derived MSCs Secrete
Cytoprotective Factors
Basal secretion from bMSCs and pMSCs was determined in
MSC cultures without islets. MSCs secrete a variety of soluble
factors that are involved in cell survival, angiogenesis and
immunoregulation. Of those factors assayed, four factors (IL-6,
HGF, VEGF, and MMP2) were detectable in cultures of bMSCs
and pMSCs without islets or cytokines (Table 3). Control samples
were the MSC culture media without MSCs. The contribution of
growth factors from culture media was minimal (,0.5% of
measured values) except with the IL-10 and MMP9 assays
(between 1–10% of measured values). During expansion as a cell
monolayer, production of HGF, VEGF and MMP-2 increased
with culture time in both cell populations. On days 1 and 3, bMSC
monolayers secreted higher levels of HGF (17.563.6 pg/ng vs.
2.260.7 pg/ng), VEGF (32.462.9 pg/ng vs. 9.462.5 pg/ng) and
MMP2 (360.7634.3 pg/ng vs. 114.169.3 pg/ng) than pMSC
monolayers. Expression of IL-6 from bMSCs demonstrated
increased production of IL-6 with cell expansion (13.161.2 pg/
ng and 22.760.2 pg/ng), while pMSC secretion of IL-6 remained
constant (16.166.5 pg/ng and 17.467.4 pg/ng) between days 1
and 3 in culture, respectively (Table 3).
When cultured as cell aggregates, MSCs exhibited a different
secretion profile. HGF, VEGF, MMP2 and IL-6 remained
detectable. However, production of these cytoprotective factors
from aggregated bMSCs was reduced in comparison to monolayer
bMSCs (Table 3). In addition, between days 1 and 3, expression of
IL-6 (0.560.1 pg/ng and 0.360.1 pg/ng), HGF (1.560.4 pg/ng
and 1.560.4 pg/ng) and MMP2 (47.266.1 pg/ng and
51.765.7 pg/ng) did not change. In contrast, pancreatic MSCs
demonstrated greater HGF and MMP2 production as cell
aggregates in comparison to monolayer cells. Production of IL-6
and VEGF was similar between aggregated and monolayer
pMSCs at both days 1 and 3.
Pro-inflammatory Cytokine Stimulation Increases
Cytoprotective Factor Release
Levels of cytoprotective factors were also determined in
islet:MSC co-cultures following pro-inflammatory cytokine expo-
sure. IL-10 production remained low in all conditions tested.
Compared to islet controls, islets exposed to cytokines had an
increase in the expression of all cytoprotective factors we assessed.
Islet:MSC co-cultures exposed to pro-inflammatory cytokines
resulted in a further increase of these factors except MMP9
(Table 4). HGF and MMP2 levels remained low in islets with or
without cytokines, while MSC aggregates alone expressed
relatively high levels. In islet:MSC co-cultures, the increase in
HGF and MMP2 production likely resulted from contributions by
MSC aggregates. MMP9 levels were undetectable from MSC
aggregates with or without cytokines. With islets, MMP9
expression was high in cytokine treated islets (25.666.8 pg/ng)
compared to untreated islets (12.562.5 pg/ng). After co-culture,
MMP9 levels decreased in a dose dependent manner
(15.163.8 pg/ng, 8.562.4 pg/ng, Table 4). A very similar pattern
was observed when human islets were co-cultured with pancreatic
derived MSCs (data not shown).
Hepatocyte Growth Factor Preserves Islet Function After
Pro-inflammatory Cytokine Exposure
When islets treated with cytokines were exposed to 2.8 mM and
20.0 mM glucose, they exhibited a loss of glucose responsiveness
with a stimulation index (SI) of 1.160.1 (n=5) (Table 5).
Percentage insulin release at 2.8 mM and 20.0 mM glucose
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icantly elevated compared to untreated islets (2.861.4% and
6.060.8% respectively, n=5). Addition of HGF to the culture
media, however, preserved the glucose responsiveness of cytokine
treated islets (SI=1.860.2, p,0.05), but insulin release at 2.8 mM
and 20.0 mM glucose remained elevated (8.061.8% and
14.162.6% respectively, n=4) compared to untreated islets
(Table 5). Recovery of insulin content from cytokine treated islets
did not improve with the addition of HGF in culture compared to
islets treated with cytokines only. The effect of HGF on islets
without cytokines was also assessed. No differences in GSIS were
observed as the SI for islet with HGF was 2.360.5 compared to
the SI for islets alone, 2.460.4.
Discussion
During islet engraftment, up to 60% of islet tissue is lost within
the first 72 hours after transplantation [5,6]. The detection of
inflammation in and around the islet graft with syngeneic and
autologous donors suggests that a non-specific immune response is
the major factor for loss of islets [5,6,25]. This inflammatory
response can be characterized by immune cell infiltration and
elevated levels of IFN-c, TNF-a, and IL-1b [5–7,10,26]. Because
the achievement of insulin independence with the Edmonton
Protocol depends on transplanting a sufficient islet mass, pre-
serving islet mass and function can prevent early graft failure and
may also decrease the requirement for multiple islet donors [3,5].
Although chemical and pharmacologic inhibition of these
cytokines can improve islet graft function [7,10,26], islet graft
specific immunosuppression would be more desirable and could be
achieved by treatment with an immunoregulatory cell such as the
MSC. Described as adult connective tissue derived stem cells with
the capacity to differentiate into osteocytes, adipocytes and
chondrocytes, MSCs are typically expanded as a cell source for
tissue replacement strategies [11–13]. However, the reduction in
inflammation, fibrosis and cell death with MSC therapy led to the
recognition that MSCs could also produce potent protective
factors for tissue repair and immunomodulation [27–30]. Here we
have proposed that the cytoprotective properties of MSCs could
protect human islets from pro-inflammatory cytokines. To in-
vestigate this hypothesis, we devised a co-culture method of islets
and MSCs and tested the effect on islet glucose stimulated insulin
secretion (GSIS) after cytokine exposure.
Previously, the favorable effects of islet:MSC co-culture for islet
function have been predominantly reported in cultures where islets
and MSCs are physically separated [14,15]. However for co-
transplantation, islets and MSC are not separated in distinct
compartments [31–33]. To better understand islet:MSC interac-
tions for transplantation, MSCs and islets need to be cultured
together in the same compartment. One approach for cell contact
based co-culture is to coat islets with a layer of MSCs to provide
a protective barrier to the immune response [16] or to facilitate
tissue engraftment [17]. Duprez et al. demonstrated that MSCs
could coat islets; and coating was enhanced with increased MSC
numbers and time in culture [16]. In our co-culture design, we did
not observe this interaction. Instead, MSCs formed aggregates,
which could physically interact with islets. The formation of MSC
aggregates in co-culture with human islets demonstrates that direct
co-culture is a promising approach to develop islet graft specific
cell therapies.
To measure the beneficial effects of this co-culture strategy, we
tested islet function (GSIS) of islet:MSC aggregates exposed to pro-
inflammatory cytokines. Although MSC monolayers are beneficial
to islet survival and function [14,15], several authors have reported
that direct co-culture does not improve islet function [16,17]. Here
we report that aggregation of MSCs with human islets can protect
human islets from pro-inflammatory cytokines, but fibroblasts are
not protective for islet function. This protective effect was not
Table 2. Effect of cytokine exposure on human islet total cellular insulin content and insulin secretory capacity.
% Recovery Insulin Release (% insulin content)
Culture Conditions Cellular Insulin Content 2.8 mM Glucose 20.0 mM Glucose Stimulation Index
Islet (n=7) 100 2.360.3 4.660.4 2.160.2
Islet + cytokine, (n=7) 34.763.2* 11.661.9* 14.363.1* 1.260.1*
Islet +0.5610
6 bMSC + cytokine (n=7) 52.865.1* 5.160.8
{ 9.061.4 1.860.2
Islet +1.0610
6 bMSC + cytokine (n=6) 68.065.3 3.661.6
{ 6.860.9
{ 2.060.2
{
Islet, (n=7) 100.0 2.860.3 5.860.9 2.260.4
Islet + cytokine (n=7) 28.765.5* 14.261.9* 15.461.8* 1.160.1*
Islet +0.5610
6 pMSC + cytokine (n=7) 35.667.4* 8.660.7
1 13.661.5 1.660.2
Islet +1.0610
6 pMSC + cytokine (n=6) 33.267.3* 6.960.8
|| 10.361.2 1.560.2
Islet, (n=4) 100.0 2.060.4 4.360.4 2.360.3
Islet + cytokine, (n=4) 32.263.9* 12.863.3* 16.965.4* 1.360.1*
Islet +0.5610
6 fibro + cytokine (n=3) 31.767.7* 9.961.5* 12.660.5* 1.360.2*
Islet +1.0610
6 fibro + cytokine (n=4) 40.365.9* 8.561.0* 13.662.7* 1.460.1*
Results are reported as % recovery of total cellular insulin content relative to untreated controls (islets alone). Islet function is assessed by a static glucose stimulated
insulin release assay. The stimulation index (SI) is calculated as a ratio of insulin release at high glucose versus low glucose. Insulin release (% insulin content) is reported
as insulin secreted at 2.8 mM glucose or 20.0 mM glucose divided by cellular insulin content for corresponding islets. Values are expressed as mean 6 SEM.
*p,0.05 for islet vs. all conditions.
{p,0.05 for islet + cytokine vs. islet +0.5610
6 bMSC + cytokine.
{p,0.05 for islet + cytokine vs. islet +1.0610
6 bMSC + cytokine.
1p,0.05 for islet + cytokine vs. islet +0.5610
6 pMSC + cytokine.
||p,0.05 for islet + cytokine vs. islet +1.0610
6 pMSC + cytokine. (bMSCs) represents bone marrow derived mesenchymal stem cells, (pMSCs) represents pancreatic
derived mesenchymal stem cells and (fibro) represents dermal fibroblasts.
doi:10.1371/journal.pone.0038189.t002
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preservation of GSIS in cytokine treated human islets is MSC
dependent. Examination for the percentage insulin release reveals
that cytokine exposure significantly increases both basal and
stimulated insulin secretion (p,0.05) compared to untreated
control islets. However, the release of insulin is not glucose
dependent, which suggests that increased insulin secretion may be
due to the cytotoxic effects of cytokines such as disruption of cell
membrane integrity (5). Hostens et al, also reported that cytokine
exposure could increase insulin release when reported as
a percentage of total cellular insulin [34]. They concluded that
their cytokine treatment altered the functional state of the b cell. In
contrast, co-culture of islets with MSCs prior to cytokine exposure
reduces percentage insulin release and maintains glucose re-
sponsive insulin secretion (Table 2). Particularly, increasing MSC
numbers to 1.0610
6 significantly improved islet function (p,0.05),
and decreased percentage insulin secretion at 2.8 mM and
20.0 mM glucose to levels that were comparable to untreated
islets. Although others have reported that direct islet:MSC
interactions do not produce beneficial effects [16,17], the
difference in MSC-islet interaction in our co-culture approach
(minimal islet:MSC coating) is a possible explanation for the
protective effects that we observed. Nevertheless, this protection is
limited because cellular insulin content was decreased in all
conditions exposed to cytokines. The difference in basal insulin
secretion of control and co-culture islets suggests that MSCs may
protect the glucose sensing but may not affect the insulin
biosynthetic function of human islets. While we have not explored
the mechanisms for this loss in insulin content, the disruptive
effects of IFN-c, TNF-a, and IL-1b on insulin biosynthesis have
been previously reported [5,8,9]. Interestingly, the recovery of
cellular insulin content was greatest with bMSCs.
In addition to impairing glucose responsiveness, IFNc, TNFa
and IL-1b can be cytotoxic to b cells. As bMSCs exhibited
protective effects on islet function, we assessed the ability of
bMSCs to prevent b cell apoptosis in our islet:MSC co-cultures.
Figure 1. Protection of human islets from cytokine induced apoptosis by bone marrow derived MSCs. A-C) 500 Islets, D-F) 500 Islets +
cytokines, G-I) 500 Islets +1.0610
6 bMSCs, + cytokines. Tissues were stained for insulin (A,D,G) in red and TUNEL (B,E,H) in green. The merge of the red
and green images are presented in panels C, F, and I. Islets cultured without cytokines demonstrated minimal TUNEL positive cells. After cytokine
exposure, the number of TUNEL positive cells increased; TUNEL and insulin co-expression was also increased with cytokine treatment. Alteration of
native islet organization was observed. After cytokine exposure, co-expression of insulin and TUNEL did not increase in the islets + bMSCs group;
cytokines – cocktail of IFNc, TNFa and IL-1b described in materials and methods. Scale bar represents 100 mm.
doi:10.1371/journal.pone.0038189.g001
MSCs Protect Human Islets
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e38189We observed that most b cells in the cytokine treated islets group
were positive for TUNEL, confirming the cytotoxicity of the pro-
inflammatory cytokine cocktail. A decrease in the number of
insulin positive cells was observed, correlating with our data
demonstrating 34.763.2% cellular insulin recovery in the
presence of cytokines. In contrast, when islets were co-cultured
with MSCs, insulin expression was maintained and fewer TUNEL
positive cells were present after cytokine treatment. Therefore we
conclude that MSCs could prevent islet b cell apoptosis in the
presence of cytokines. Islet structure is also important for islet
function. We observed that islet morphology was altered after
cytokine exposure but the morphology of islets from co-culture
and controls remained intact, correlating with the reported effects
on islet function. These results suggest that the mechanisms
underlying the protective effect of MSCs on b cells involve the
mitigation of cell death pathways and the retention of native islet
morphology. Identifying the signals from islet:bMSC co-cultures
may be a strategy to enhance this protection.
As MSCs but not fibroblasts from different tissue sources induce
similar effects on human islet function, a common MSC specific
secreted factor may mediate these effects. We investigated the
cytoprotective factors IL-6, IL-10, HGF, VEGF, MMP2, and
MMP9 because of their reported beneficial effects on islets
[14,15,35] and in islet transplantation [31,33,36,37]. HGF, for
instance, can signal pathways regulating cell survival and insulin
secretion [15]. IL-6, on the other hand, prevented the functional
impairment of IFN-c, TNF-a, and IL-1b treated mouse islets [38].
Basal secretion levels from monolayer and aggregated MSCs were
initially tested. IL-6, HGF, VEGF and MMP2 were consistently
detected from both pancreas and bone marrow MSC monolayers,
but IL-10 and MMP9 levels were low. Expression of these factors
was also greater from bMSCs than pMSCs. Berman et al. reported
similar findings, as monkey MSCs expressed IL-6, HGF and
VEGF genes; whereas IL-10 gene expression remained low during
monolayer expansion [37]. The three dimensional microenviron-
ment of aggregated MSCs is unique from the two dimensional
MSC monolayer. We wanted to determine whether basal
production of soluble factors was markedly different with
aggregated MSCs. In general, aggregated MSCs also express IL-
6, HGF, VEGF and MMP2. An intriguing trend emerged in
which bMSC aggregates had markedly decreased cytoprotective
factor expression but pMSCs exhibited increased expression of
Table 3. Basal secretion of growth factors and cytokines from human bone marrow and pancreatic derived mesenchymal stem
cells.
(pg protein/ng DNA)
Conditions MSC Days Cultured IL-6 IL-10 HGF VEGF MMP2 MMP9
Monolayer b 1 13.161.2 0.060.0 2.160.2 12.062.1 114.466.7 0.360.2
Monolayer b 3 22.760.2 0.160.0 17.563.6 32.363.9 360.7634.3 0.560.2
Monolayer p 1 16.166.5 0.060.0 0.560.1 2.660.3 81.762.7 0.260.1
Monolayer p 3 17.467.4 0.060.0 2.260.7 9.462.5 114.169.3 0.060.0
Aggregate b 1 0.560.1 0.060.0 1.560.4 1.560.3 47.266.1 0.260.0
Aggregate b 3 0.360.1 0.060.0 1.560.4 3.460.8 51.765.7 0.260.1
Aggregate p 1 9.163.3 0.160.0 3.060.5 2.860.5 112.364.8 0.160.0
Aggregate p 3 25.667.3 0.160.0 17.963.2 12.662.6 312.0616.2 2.361.1
Levels of cytoprotective factors were measured from conditioned culture media, where bone marrow and pancreatic MSCs were cultured alone as either a cell
monolayer or cellular aggregates. Values obtained from cell cultures were subtracted from background levels (,0.5% of measured values for IL-6, HGF, VEGF, MMP2 and
1–10% of measured values for IL-10, MMP9) measured in culture media alone. All values are normalized to the DNA contents of each culture condition. Values are
expressed as mean 6 SEM (n=3). (b) represents bone marrow and (p) represents pancreas derived MSCs.
doi:10.1371/journal.pone.0038189.t003
Table 4. Secretion of growth factors and cytokines from human islet and bone marrow MSC co-cultures.
(pg protein/ng DNA)
IL-6 IL-10 HGF VEGF MMP2 MMP9
Islet 9.662.7 0.060.0 0.160.0 2.860.5 3.460.5 12.562.5
Islet + cytokine 21.164.4 0.160.0 0.160.0 5.560.4 5.760.9 25.666.8
Islet +0.5610
6 bMSC + cytokine 33.869.5 0.160.0 3.261.0* 8.661.5 95.8618.7* 15.163.8
Islet +1.0610
6 bMSC + cytokine 24.265.3 0.160.0 3.461.0* 7.760.9 94.5619.8* 8.562.4
0.5610
6 bMSC 1.460.2 0.060.0 6.062.6* 6.860.6 144.2621.8* 0.360.2*
0.5610
6 bMSC+ cytokine 44.664.8 0.260.0 4.461.0* 3.760.4 165.4612.7* 0.260.1*
Levels of cytoprotective factors were also measured from conditioned media from islets cultured alone, with cytokines and with bone marrow MSCs with and without
cytokines. Values obtained from cell cultures were subtracted from background levels (,0.5% of measured values for IL-6, HGF, VEGF, MMP2 and 1–10% of measured
values for IL-10, MMP9) measured in culture media alone. All values are normalized to the DNA contents of each culture condition. Values are expressed as mean 6 SEM
(n=5).
*p,0.05 for islet + cytokine vs. all conditions.
doi:10.1371/journal.pone.0038189.t004
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factor production suggests that MSC function is dependent on
tissue source and culture method as a cell monolayer or cellular
aggregates. To better define the factors mediating protection of
islets, we examined the production of these cytoprotective factors
from islet:MSC co-cultures. As bMSCs exhibited the greatest
protective effect, we selected the islet:bMSC co-cultures to
determine expression profiles. HGF and MMP2 were MSC
specific, and production increased with increasing numbers of
MSCs (Table 4). We also observed that while MMP9 levels
decreased, islet function improved with increasing MSC numbers,
which suggests that bMSCs may protect by mitigating excessive
MMP9 expression. Others reported that islets cultured in medium
composed of IL-6, TGF-b, HGF and VEGF had significantly
improved function [15]. In our co-culture system HGF, MMP2
and MMP9 appeared to be important MSC dependent factors
associated with improved islet function after cytokine treatment.
Addition of HGF to cytokine treated islets resulted in preservation
of glucose responsiveness based on the stimulation index (p,0.05).
Basal and stimulated insulin release, on the other hand, was
elevated compared to untreated islets (p,0.05). In addition,
recovery of insulin content was not improved with HGF (Table 5);
whereas, islets co-cultured with bMSCs demonstrated better
insulin content recovery than cytokine treated islets (Table 2). As
HGF alone was unable to completely reproduce the effects of
bMSC, we did not proceed to inhibit the activity of HGF in co-
culture. Based on these results, we believe that other factors in
addition to HGF such as MMP2, MMP9 and TGF-b may be
important for cytoprotection of islet function.
In summary, MSC aggregates preserved GSIS and prevented
islet b cell apoptosis of pro-inflammatory cytokine treated islets.
The absence of this protective phenomenon with human dermal
fibroblasts strongly suggests that preservation of GSIS is MSC
dependent. Assessment of the secreted factors from MSCs
demonstrates that HGF, MMP2 and MMP9 are possible secreted
factors mediating protection. However, addition of rhHGF to islet
cultures reveals that HGF alone cannot replace the beneficial
effects of MSCs. Although the mechanism of protection is unclear,
future studies can address the ability of MSCs to attenuate
inflammation mediated b-cell graft dysfunction. Replicating these
results in vivo will help develop a strategy to administer MSCs for
clinical islet transplantation and to prolong graft survival and
function.
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